AN2 Therapeutics, Inc. – NASDAQ:ANTX
AN2 Therapeutics stock price today
$1.15
-0.29
-20.14%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
AN2 Therapeutics stock price monthly change
-44.19%
month
AN2 Therapeutics stock price quarterly change
-44.19%
quarter
AN2 Therapeutics stock price yearly change
-93.14%
year
AN2 Therapeutics key metrics
Market Cap | 41.23M |
Enterprise value | 114.73M |
P/E | -3.29 |
EV/Sales | N/A |
EV/EBITDA | -1.88 |
Price/Sales | N/A |
Price/Book | 1.48 |
PEG ratio | 0.04 |
EPS | -2.59 |
Revenue | N/A |
EBITDA | -71.89M |
Income | -66.02M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAN2 Therapeutics stock price history
AN2 Therapeutics stock forecast
AN2 Therapeutics financial statements
| Jun 2023 | 0 | -15.80M | |
|---|---|---|---|
| Sep 2023 | 0 | -16.70M | |
| Dec 2023 | 80K | -16.89M | -21122.5% |
| Mar 2024 | 0 | -16.61M |
| Mar 2024 | 0 | -16.61M | |
|---|---|---|---|
| Sep 2025 | 0 | -21.11M | |
| Oct 2025 | 0 | -20.53M | |
| Dec 2025 | 0 | -20.53M |
Analysts Price target
Financials & Ratios estimates
| 2023-11-09 | -0.63 | -0.65 |
|---|---|---|
| 2024-03-28 | -0.71 | -0.57 |
| 2024-05-14 | -0.61 | -0.56 |
| Jun 2023 | 98926000 | 11.16M | 11.28% |
|---|---|---|---|
| Sep 2023 | 153808000 | 14.83M | 9.65% |
| Dec 2023 | 138744000 | 14.04M | 10.12% |
| Mar 2024 | 121260000 | 10.66M | 8.79% |
| Jun 2023 | -12.82M | 7.87M | 19.05M |
|---|---|---|---|
| Sep 2023 | -11.8M | -62.46M | 66.06M |
| Dec 2023 | -17.06M | 420K | -321K |
| Mar 2024 | -17.59M | 26.29M | 349K |
AN2 Therapeutics alternative data
| Aug 2023 | 35 |
|---|---|
| Sep 2023 | 35 |
| Oct 2023 | 35 |
| Nov 2023 | 35 |
| Dec 2023 | 35 |
| Jan 2024 | 35 |
| Feb 2024 | 35 |
| Mar 2024 | 35 |
| Apr 2024 | 35 |
| May 2024 | 41 |
| Jun 2024 | 41 |
| Jul 2024 | 41 |
AN2 Therapeutics other data
7.18%
-43.28%
of ANTX is owned by hedge funds
21
-15
1.10M
-8.66M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 317871 |
| Aug 2024 | 1500000 | 3525094 |
| Nov 2024 | 352000 | 0 |
| Dec 2024 | 60000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | READNOUR ROBIN SHANE director | Common Stock | 5,000 | $1.49 | $7,470 | ||
Purchase | READNOUR ROBIN SHANE director | Common Stock | 5,000 | $1.49 | $7,460 | ||
Purchase | READNOUR ROBIN SHANE director | Common Stock | 18,483 | $1.43 | $26,412 | ||
Purchase | READNOUR ROBIN SHANE director | Common Stock | 12,289 | $1.43 | $17,573 | ||
Purchase | READNOUR ROBIN SHANE director | Common Stock | 6,517 | $1.45 | $9,430 | ||
Purchase | READNOUR ROBIN SHANE director | Common Stock | 12,711 | $1.45 | $18,367 | ||
Purchase | READNOUR ROBIN SHANE director | Common Stock | 25,000 | $1.42 | $35,425 | ||
Purchase | READNOUR ROBIN SHANE director | Common Stock | 25,000 | $1.42 | $35,425 | ||
Purchase | ZAKRZEWSKI JOSEPH S director | Common Stock | 2,000 | $1.4 | $2,800 | ||
Purchase | READNOUR ROBIN SHANE director | Common Stock | 12,500 | $1.39 | $17,425 |
-
What's the price of AN2 Therapeutics stock today?
One share of AN2 Therapeutics stock can currently be purchased for approximately $1.15.
-
When is AN2 Therapeutics's next earnings date?
Unfortunately, AN2 Therapeutics's (ANTX) next earnings date is currently unknown.
-
Does AN2 Therapeutics pay dividends?
No, AN2 Therapeutics does not pay dividends.
-
How much money does AN2 Therapeutics make?
AN2 Therapeutics has a market capitalization of 41.23M. AN2 Therapeutics made a loss 64.73M US dollars in net income (profit) last year or -$0.56 on an earnings per share basis.
-
What is AN2 Therapeutics's stock symbol?
AN2 Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ANTX".
-
What is AN2 Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of AN2 Therapeutics?
Shares of AN2 Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does AN2 Therapeutics have?
As Jul 2024, AN2 Therapeutics employs 41 workers, which is 17% more then previous quarter.
-
When AN2 Therapeutics went public?
AN2 Therapeutics, Inc. is publicly traded company for more then 3 years since IPO on 25 Mar 2022.
-
What is AN2 Therapeutics's official website?
The official website for AN2 Therapeutics is an2therapeutics.com.
-
Where are AN2 Therapeutics's headquarters?
AN2 Therapeutics is headquartered at 1800 El Camino Real, Menlo Park, CA.
-
How can i contact AN2 Therapeutics?
AN2 Therapeutics's mailing address is 1800 El Camino Real, Menlo Park, CA and company can be reached via phone at +65 03319090.
AN2 Therapeutics company profile:
AN2 Therapeutics, Inc.
an2therapeutics.comExchange:
NASDAQ
Full time employees:
41
Industry:
Biotechnology
Sector:
Healthcare
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
1800 El Camino Real
Menlo Park, CA 94027
Menlo Park, CA 94027
CIK: 0001880438
ISIN: US0373261058
CUSIP: 037326105
